Atea Pharmaceuticals (AVIR) announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on Antiviral Research, ICAR, 2025 taking place March 17-21, 2025 in Las Vegas, Nevada. “The results presented at ICAR highlight Atea’s deep scientific expertise in antiviral drug development by demonstrating metabolism of nucleotide prodrugs, such as bemnifosbuvir, is highly cell-line dependent and cell model selection needs to be taken into account when evaluating in vitro antiviral efficacy,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and founder of Atea. “Bemnifosbuvir is being developed in a fixed dose combination regimen with ruzasvir for the treatment of hepatitis C virus. We look forward to starting patient enrollment in the Phase 3 program evaluating this potential best-in-class HCV regimen in April.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts
- Atea Pharmaceuticals’ Promising Earnings Call Highlights
- Atea Pharmaceuticals Advances HCV Program with FDA Approval
- Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)
- AVIR Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue